Evidence map›Paper›PMID 26140240›Full record

ArticleOncoimmunology2015

Local

Sonia Domingos-Pereira, Rim Hojeij, Erica Reggi, Laurent Derré, Mathieu F Chevalier, Pedro Romero, Patrice Jichlinski, Denise Nardelli-Haefliger

Abstract read
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Modulation ofTheranostics · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sonia Domingos-PereiraDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.
Rim HojeijDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.
Erica ReggiDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.
Laurent DerréDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.
Mathieu F ChevalierDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.
Pedro RomeroLudwig Center for Cancer Research of University of Lausanne ; Lausanne, Switzerland.
Patrice JichlinskiDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.
Denise Nardelli-HaefligerDept. Urology; Lausanne University Hospital (CHUV); Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and augment antitumoral CD8 T cells in the genital mucosa (GM) and increase regression of cervical cancer in an animal model. Non muscle-invasive bladder cancer is another disease that is easily amenable to local therapies. In contrast to data obtained in the GM, in this study we show that intravesical (IVES) instillation of synthetic toll-like receptor (TLR) agonists only modestly induced recruitment of CD8 T cells to the bladder. However, IVES administration of Ty21a, a live bacterial vaccine against typhoid fever, was much more effective and increased the number of total and vaccine-specific CD8 T cells in the bladder approximately 10 fold. Comparison of chemokines induced in the bladder by either CpG (a TLR-9 agonist) or Ty21a highlighted the preferential increase in complement component 5a, CXCL5, CXCL2, CCL8, and CCL5 by Ty21a, suggesting their involvement in the attraction of T cells to the bladder. IVES treatment with Ty21a after vaccination also significantly increased tumor regression compared to vaccination alone, resulting in 90% survival in an orthotopic murine model of bladder cancer expressing a prototype tumor antigen. Our data demonstrate that combining vaccination with local immunostimulation may be an effective treatment strategy for different types of cancer and also highlight the great potential of the Ty21a vaccine, which is routinely used worldwide, in such combinatorial therapies.

Indexed as

bacterial immunostimulantBCG, Bacillus Calmette Guerinbladder cancerBMDC, bone marrow-derived dendritic cellC5a, complement component 5acombinatorial therapyESL, E-selectin ligandsGM, genital mucosaIVAG, intravaginalIVES, intravesicalNMIBC, non-muscle invasive bladder cancerPBS, phosphate buffered salinePE, phycoerythrinPIC, poly (I:C)Salmonella Ty21as.c., subcutaneouslySEM, standard error of the meantherapeutic vaccinationTLR, toll-like receptorTUR, transurethral resection

Identifiers

PMID26140240
PMCPMC4485756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.